[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0507420A - composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência - Google Patents

composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência

Info

Publication number
BRPI0507420A
BRPI0507420A BRPI0507420-7A BRPI0507420A BRPI0507420A BR PI0507420 A BRPI0507420 A BR PI0507420A BR PI0507420 A BRPI0507420 A BR PI0507420A BR PI0507420 A BRPI0507420 A BR PI0507420A
Authority
BR
Brazil
Prior art keywords
antiflatulence
compositions
statin
starch
agent
Prior art date
Application number
BRPI0507420-7A
Other languages
English (en)
Inventor
Marta Guerrero
Anna Orriols
Manuel M Raga
Antonio Guglietta
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of BRPI0507420A publication Critical patent/BRPI0507420A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçõES HIPOCOLESTEROLêMICAS COMPREENDENDO UMA ESTATINA E UM AGENTE ANTIFLATULêNCIA A presente invenção refere-se às composições hipocolesterolêmicas compreendendo estatinas mais agentes antiflatulência. Especificamente, as composições da presente invenção compreendem uma estatina selecionada do grupo consistindo em atorvastatina, cerivastatina, fluvastatina, lovastatina, pituvastatina, rosuvastatina e sinvastatina, quer na forma ou como sais farmaceuticamente aceitáveis e hidratos das mesmas, mais um agente antiflatulência selecionado do grupo consistindo em simeticona e dimeticona. A combinação de estatinas mais agentes antiflatulência é útil na prevenção e gerenciamento da flatulência causada pelas estatinas.
BRPI0507420-7A 2004-02-03 2005-02-02 composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência BRPI0507420A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002317A EP1563837A1 (en) 2004-02-03 2004-02-03 Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
PCT/EP2005/001038 WO2005074915A1 (en) 2004-02-03 2005-02-02 Hypocholesterolemic compositions comprising a statin and an antiflatulent agent

Publications (1)

Publication Number Publication Date
BRPI0507420A true BRPI0507420A (pt) 2007-06-26

Family

ID=34684647

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507420-7A BRPI0507420A (pt) 2004-02-03 2005-02-02 composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência

Country Status (15)

Country Link
US (1) US20080206328A1 (pt)
EP (2) EP1563837A1 (pt)
JP (1) JP2007520514A (pt)
KR (1) KR100815713B1 (pt)
CN (1) CN101094667A (pt)
AR (1) AR048668A1 (pt)
AU (1) AU2005210117A1 (pt)
BR (1) BRPI0507420A (pt)
CA (1) CA2556181A1 (pt)
NO (1) NO20063867L (pt)
PA (1) PA8622701A1 (pt)
PE (1) PE20050688A1 (pt)
TW (1) TW200529818A (pt)
UY (1) UY28729A1 (pt)
WO (1) WO2005074915A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1006879B (el) * 2005-09-14 2010-07-13 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
JP2009534459A (ja) 2006-04-26 2009-09-24 ローズモント・フアーマシユーテイカルズ・リミテツド 液体経口組成物
CA2621134C (en) * 2006-05-12 2011-07-26 Pharmathen S.A. Pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
CN101229187B (zh) * 2007-01-23 2011-09-28 德国柏林化学股份有限公司 西甲硅油乳剂及其制备方法
WO2013164257A1 (en) * 2012-04-30 2013-11-07 F. Hoffmann-La Roche Ag New formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444764A (en) * 1979-08-06 1984-04-24 The Dow Chemical Company Phosphorus esters of alkylcycloalkyl-5-pyrimidinols and control of corn rootworm and western spotted cucumber beetle with them
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
DE3322770C2 (de) * 1983-06-24 1985-10-03 Deutsche Gesellschaft für Wiederaufarbeitung von Kernbrennstoffen mbH, 3000 Hannover Vorrichtung zur Handhabung und zum Schutz von Lagergebinden für radioaktive Stoffe
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1995001780A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate combinations
CA2419206A1 (en) * 2000-07-27 2002-02-07 Plus Chemicals B.V. Highly purified simvastatin compositions
WO2002067901A1 (en) * 2001-02-22 2002-09-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
EP1465605A1 (en) * 2002-01-11 2004-10-13 Athpharma Limited Pravastatin pharmaceutical formulations and methods of their use
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
ZA200501508B (en) * 2002-09-03 2006-10-25 Biovail Lab Inc Pharmaceuticals formulations and methods for modified release of statin drugs

Also Published As

Publication number Publication date
EP1563837A1 (en) 2005-08-17
AU2005210117A1 (en) 2005-08-18
AR048668A1 (es) 2006-05-17
CN101094667A (zh) 2007-12-26
TW200529818A (en) 2005-09-16
JP2007520514A (ja) 2007-07-26
KR20060118579A (ko) 2006-11-23
NO20063867L (no) 2006-10-26
PE20050688A1 (es) 2005-10-14
PA8622701A1 (es) 2005-08-10
EP1713469A1 (en) 2006-10-25
UY28729A1 (es) 2005-03-31
KR100815713B1 (ko) 2008-03-20
US20080206328A1 (en) 2008-08-28
CA2556181A1 (en) 2005-08-18
WO2005074915A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
HRP20080525A2 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A HMG CoA REDUCTASE INHIBITOR
WO2006017698A3 (en) Novel statin pharmaceutical compositions and related methods of treatment
MX2007004179A (es) Derivados de triazolpiridina como agentes antibacterianos.
RS50419B (sr) Sastav koji ne poseduje askorbinsku kiselinu i koji sadrži inhibitor apsorpcije holesterola, hmg-coa reduktaze i stabilizujući agens
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
EA200970291A1 (ru) Фармацевтическая композиция, содержащая розувастатин кальция
ATE537827T1 (de) Pharmazeutische zubereitung mit hervorragender photostabilität
AR081032A1 (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
IL174536A (en) Combination comprising candesartan and rosuvastatin, pharmaceutical compositions comprising such combination and use of such combination as a medicament for the prevention or treatment of atherosclerosis or cardiovascular events
PE106999A1 (es) Composicion de amlodipina y una estatina
BRPI0507420A (pt) composições hipocolesterolêmicas compreendendo uma estaina e um agente antiflatulência
AR074204A1 (es) Arilpiperazinas y su uso como antagonistas alfa -2c
ATE240934T1 (de) Wasserhaltiges, kristallines calcium-salz der simvastatin dihydroxy offene säure
ATE489093T1 (de) Heilmittel für hyperlipidämie
WO2008020314A3 (en) Statin stabilizing dosage formulations
BR112014003529A2 (pt) combinações de corroles e estatinas
RU2007148908A (ru) Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
WO2007117563A3 (en) 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and use thereof
BRPI0417747A (pt) uso de compostos orgánicos
GR20050100466A (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
BRPI0500101A (pt) Composições bifásicas contendo álcool
NZ603397A (en) Association of xanthine oxidase inhibitors and statins and use thereof
JP2004083588A5 (pt)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.